The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 26, 2020

Filed:

Feb. 15, 2017
Applicant:

University of Southern California, Los Angeles, CA (US);

Inventors:

Valter D. Longo, Playa del Rey, CA (US);

Roberta Buono, Los Angeles, CA (US);

Assignee:

UNIVERSITY OF SOUTHERN CALIFORNIA, Los Angeles, CA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/02 (2006.01); A23L 33/00 (2016.01); A23L 33/10 (2016.01); A61K 31/375 (2006.01); A61K 31/4415 (2006.01); A61K 31/525 (2006.01); A61K 31/51 (2006.01); A61K 31/4188 (2006.01); A61K 31/07 (2006.01); A61K 33/32 (2006.01); A61K 33/04 (2006.01); A61K 33/06 (2006.01); A61K 31/519 (2006.01); A61K 31/455 (2006.01); A61K 33/26 (2006.01); A61K 31/197 (2006.01); A61K 33/34 (2006.01); A23L 33/12 (2016.01); A23L 33/17 (2016.01); A23L 33/115 (2016.01); A23L 33/16 (2016.01); A23L 33/125 (2016.01); A23L 33/15 (2016.01); A23L 33/155 (2016.01); A61K 31/70 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
A61K 38/02 (2013.01); A23L 33/10 (2016.08); A23L 33/115 (2016.08); A23L 33/12 (2016.08); A23L 33/125 (2016.08); A23L 33/15 (2016.08); A23L 33/155 (2016.08); A23L 33/16 (2016.08); A23L 33/17 (2016.08); A23L 33/30 (2016.08); A23L 33/40 (2016.08); A61K 31/07 (2013.01); A61K 31/197 (2013.01); A61K 31/375 (2013.01); A61K 31/4188 (2013.01); A61K 31/4415 (2013.01); A61K 31/455 (2013.01); A61K 31/51 (2013.01); A61K 31/519 (2013.01); A61K 31/525 (2013.01); A61K 31/70 (2013.01); A61K 33/04 (2013.01); A61K 33/06 (2013.01); A61K 33/26 (2013.01); A61K 33/32 (2013.01); A61K 33/34 (2013.01); A61K 45/06 (2013.01); A23V 2002/00 (2013.01);
Abstract

Stem cell-based therapies can potentially reverse organ dysfunction and diseases but the removal of impaired tissue and reactivation of the program leading to organ regeneration pose major challenges. In mice, a four-day fasting mimicking diet (FMD) induces a step-wise expression of Sox17 and Pdx-1, resembling that observed during pancreatic development and followed by Ngn3-driven generation of insulin-producing β-cells. FMD cycles restore insulin secretion and glucose homeostasis in both a type 2 and type 1 diabetes mouse models. In human type 1 diabetes pancreatic islets, fasting conditions reduce PKA and mTOR activity and induce Sox2 and Ngn3 expression and insulin production. The effects of the FMD are reversed by IGF-1 treatment and recapitulated by PKA and mTOR inhibition. These results indicate that a FMD promotes the reprogramming of pancreatic cells to restore insulin generation in islets from T1D patients and reverse both T1D and T2D phenotypes in mouse models.


Find Patent Forward Citations

Loading…